Archive for January 26th, 2010

The European Medicines Agency (EMA) has finalised a review of Tysabri (natalizumab) and the risk of progressive multifocal leukoencephalopathy (PML), a rare brain infection caused by the JC virus. The Agency’s Committee for Medicinal Products for Human Use (CHMP) has concluded that the risk of developing PML increases after two years of use of Tysabri although this risk remains low…

The US Food and Drug Administration (FDA) has approved a drug which has been found to allow people with multiple sclerosis (MS) to walk faster. People treated with the drug Ampyra (dalfampridine) were found in clinical trials to have faster walking speeds than those treated with a placebo, the American drug watchdog found…

PROLOR Biotech, Inc., (OTC Bulletin Board: PBTH) reported positive results from a comparative study in primates of its longer-acting version of the multiple sclerosis drug interferon beta (IFN-beta-1a-CTP, referred to as IFN-beta-CTP)…